PBLS Parabilis Medicines, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1657677 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets11.2%
Debt / equity0.00x
Current ratio12.88x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $2.11M | $148,000 | — | $0 | $0 | — |
| R&D expense | $45.60M | $39.38M | — | $28.20M | $30.13M | — |
| SG&A expense | $11.25M | $11.66M | — | $6.65M | $6.39M | — |
| Operating income | -$54.74M | -$50.89M | — | -$34.84M | -$36.52M | — |
| Interest expense | $124,000 | $210,000 | — | $398,000 | $396,000 | — |
| Net income | -$44.49M | -$52.46M | -$45.32M | -$33.48M | -$34.81M | -$38.33M |
| EBITDA | -$54.14M | -$50.29M | — | -$34.74M | -$36.32M | — |
| EPS (basic) | -0.36 | -2.32 | — | -21.66 | -22.28 | — |
| EPS (diluted) | -0.36 | -2.32 | — | -21.66 | -22.28 | — |
| Weighted avg. shares (diluted) | 123.59M | 28.91M | — | 2.03M | 2.02M | — |
| Balance sheet | ||||||
| Cash & equivalents | $521.20M | $1.09B | — | $57.40M | $80.39M | — |
| Short-term investments | $350.43M | $33.64M | — | — | — | — |
| Receivables | $443,000 | — | — | — | — | — |
| Current assets | $879.02M | $1.13B | — | — | — | — |
| PP&E, net | $9.51M | $6.72M | — | — | — | — |
| Total assets | $1.13B | $1.18B | — | — | — | — |
| Current liabilities | $68.26M | $62.84M | — | — | — | — |
| Short-term debt | $2.00M | $5.71M | — | — | — | — |
| Long-term debt | — | $700,000 | — | — | — | — |
| Total debt | — | $6.41M | — | — | — | — |
| Total liabilities | $126.89M | $127.53M | — | — | — | — |
| Shareholders' equity | $1.00B | $1.05B | -$570.32M | -$488.05M | -$455.41M | -$421.43M |
| Net debt | — | -$1.08B | — | — | — | — |
| Shares outstanding | 122.08M | 121.94M | — | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$41.08M | — | — | -$31.54M | — | — |
| Capital expenditure | $611,000 | — | — | $93,000 | — | — |
| Free cash flow | -$41.69M | — | — | -$31.63M | — | — |
| Investing cash flow | -$518.28M | — | — | $8.68M | — | — |
| Financing cash flow | -$6.50M | — | — | -$137,000 | — | — |
| Depreciation & amortization | $600,000 | $600,000 | — | $100,000 | $200,000 | — |
| Stock-based compensation | $2.74M | $3.63M | — | $820,000 | $823,000 | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.